long intergenic non-protein coding RNA 702Genealiases: []
Q-omics provides the consensus-scored LINC00702 profile across patient tissues and cancer cell-line models. LINC00702 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC00702 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, LINC00702 RNA expression shows 23,329 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, COAD, and BRCA as cancer lineages where LINC00702 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00702 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00702 survival associations across molecular data types. LINC00702 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00702 RNA expression–survival associations across cancer types. High LINC00702 expression shows unfavorable associations in KIRP, UVM, MESO, BLCA, CESC and LAML. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC00702 RNA expression.
This table summarizes LINC00702 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00702. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00702 shows lower tumor expression in COAD, LUAD, BLCA, LUSC and THCA and higher tumor expression in LIHC. The COAD box plot shows higher LINC00702 RNA expression in normal versus tumor tissue (log2 FC = −0.653, t-test p < 0.001).
This table shows molecular features associated with LINC00702 in patient tissues and cancer cell lines. In patient samples, LINC00702 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
